CD5 Expression in Marginal Zone Lymphoma (MZL) Predicts Worse Outcomes with Rituximab (R) but Not with Bendamustine/Rituximab (BR)

Hsu, A; Zayac, A; Kurt, H; Olszewski, AJ

BLOOD, 2020; 136 ():